Filing Date |
T Date |
Ticker |
Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
#f |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4/7/26 20:57 | 4/7/26 | MGTX | Health | BioPrd | Biological Products, (No Diag | Naylor Stuart | NY | O | CHIEF DE | 3 | S.d | -259 | 2.03 | 0 | -128 | 696 | D | |||||||||||||||
3/24/26 21:12 | 3/24/26 | MGTX | Health | BioPrd | Biological Products, (No Diag | Forbes Alexandria | NY | DO | P,CEO | 3 | S.d | -459 | 1.06 | 0 | -435 | 1,512 | D | |||||||||||||||
2/23/26 21:25 | 2/21/26 | MGTX | Health | BioPrd | Biological Products, (No Diag | Zeldin Robert K | NY | O | CHIEF ME | 2 | M.d | 0 | 0.00 | 0 | 43 | 33 | 173 | D | ||||||||||||||
2/23/26 21:24 | 2/21/26 | MGTX | Health | BioPrd | Biological Products, (No Diag | Wollin Robert J | NY | O | GC,SECRE | 2 | M.d | 0 | 0.00 | 0 | 61 | 57 | D | |||||||||||||||
2/23/26 21:19 | 2/21/26 | MGTX | Health | BioPrd | Biological Products, (No Diag | Giroux Richard | NY | O | CFO,COO | 2 | M.d | 0 | 0.00 | 0 | 370 | 49 | 1,118 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |